DONGGOU(David) HE，M.D.,Ph.D.

DONGGOU(David) HE, M.D., Ph.D. has held various leadership positions in the biopharmaceutical industry. DONGGOU(David) is currently serving as the Executive Vice President and CTO at IASO BioTherapeutics, where they provide strategic direction and technical leadership to multiple departments. Prior to this, they worked as the Chief Technical Officer at Clover Biopharmaceuticals, overseeing the management of key functional teams. DONGGOU(David) also served as the Vice President of Technical Operations at Legend Biotech, where they established and led various departments. Dr. DONGGOU(David) has also gained experience at Boehringer Ingelheim, ASKGENE PHARMA, Goodwin Biotechnology, ADV Biologics Inc, and the University of Alabama at Birmingham, where they held positions focused on process development, immunology, and tumor immunotherapy. DONGGOU(David) started their career as an Associate Professor at Guangzhou Medical University, conducting research in tumor immunology and antibody discovery.

DONGGOU (David) HE, M.D., Ph.D. obtained their Medical Degree in Clinical Medicine from Hengyang Medical College in the years 1983 to 1988. DONGGOU(David) then pursued a Master's degree in Tumor Cell Biology and Immunology at Guangzhou Medical University from 1991 to 1994. Continuing their academic journey, they completed their Ph.D. in Pathogen Biology and Molecular Biology at Sun Yat-sen University from 2001 to 2004. To further specialize in their field, they conducted postdoctoral research in Cellular Immunology and Dermatology at the University of Alabama at Birmingham from 2004 to 2007.